Filing Context
The provided filing is Selecta Biosciences, Inc.’s Form 10-Q for the quarter ended March 31, 2017, not Cartesian Therapeutics, Inc. The company was a clinical-stage biopharmaceutical developer of synthetic vaccine particle (SVP) technology. Its lead candidate, SEL-212, was in a Phase 1/2 program, with the Phase 2 trial initiated in October 2016. The financial statements are unaudited and presented under U.S. GAAP.
Financial Results and Position
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Grant and collaboration revenue | $0.1 million | $2.1 million | Down 93% |
| Research and development expense | $11.0 million | $6.6 million | Up 66% |
| General and administrative expense | $3.9 million | $2.4 million | Up 63% |
| Loss from operations | $14.8 million | $6.9 million | Loss increased |
| Net loss | $15.1 million | $7.5 million | Loss increased 102% |
| Net loss per share | $0.82 | $4.52 | Per-share loss decreased due to higher share count |
| Net cash used in operating activities | $15.3 million | $10.2 million | Use increased |
Revenue was immaterial relative to operating expenses, so operating and net margins were not economically meaningful for this development-stage company. Research and development spending increased primarily because SEL-212 advanced into Phase 2, with higher external development, manufacturing, clinical, personnel and stock-based compensation costs.
- Cash and cash equivalents at March 31, 2017 were $26.6 million, compared with $58.7 million at December 31, 2016.
- Short-term investments were $41.9 million, compared with $25.5 million at year-end 2016.
- Cash, short-term investments and restricted cash totaled approximately $68.6 million.
- Total assets were $73.9 million and stockholders’ equity was $41.1 million.
- Accumulated deficit was $166.7 million, compared with $151.6 million at December 31, 2016.
- Outstanding term-loan principal was $11.3 million, with $4.5 million classified as current and $6.9 million as long-term debt. The loans bear interest at approximately 8.1% and mature in 2019.
- Net cash used in investing activities was $16.5 million, primarily reflecting purchases of short-term investments. Financing activities used $0.3 million, including $0.7 million of principal repayments and $0.4 million from option exercises.
Material Changes Versus Prior Comparable Period
- Total revenue declined by $2.0 million, primarily because of a $1.8 million reduction in revenue from the NIDA grant and lower collaboration revenue following the Sanofi termination notice.
- Research and development expense increased by $4.4 million, including approximately $2.8 million of additional external SEL-212 costs as the company transitioned toward Phase 2, $0.6 million for SEL-110 and other pipeline programs, and $0.5 million of additional compensation.
- General and administrative expense increased by $1.5 million due to headcount growth, public-company compliance, consulting, accounting, patent and stock-based compensation costs.
- The company adopted ASU 2016-09 for employee share-based payment accounting in the quarter. The filing states that the adoption increased net operating loss deferred tax assets by approximately $0.3 million, offset by a valuation allowance.
- The company issued 113,643 common shares upon option exercises during the quarter, increasing shares outstanding to 18,552,385 at March 31, 2017.
Guidance, Outlook, Risks and Unusual Items
- Management expected cash, cash equivalents, short-term investments and restricted cash at March 31, 2017 to fund operating and capital requirements into the middle of 2018, subject to assumptions that could prove incorrect.
- The company expected continuing and increasing losses as it advanced SEL-212, developed other candidates, pursued regulatory approvals, expanded infrastructure and prepared for potential manufacturing and commercialization.
- Sanofi’s termination became effective May 8, 2017. The company will receive no further payments under that agreement and assumed responsibility for any future development of the returned programs it elects to pursue.
- The Spark license and option agreement generated less than $0.1 million of revenue in the quarter and resulted in approximately $12.2 million of deferred revenue at March 31, 2017, including $1.9 million current and $10.3 million long term.
- On April 27, 2017, the company entered into an NIH/National Cancer Institute patent license for anti-mesothelin targeted immunotoxins. Consideration includes a $50,000 upfront payment, low-single-digit royalties, up to $9.3 million of benchmark payments and sublicense revenue sharing.
- Key risks included the need for additional capital, recurring losses and negative operating cash flow, uncertain clinical and regulatory outcomes, possible adverse events, dependence on third-party manufacturers and 3SBio for pegsiticase, intellectual-property risks, collaboration termination, foreign-currency exposure and restrictive debt covenants.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls were effective as of March 31, 2017.
Investor Verification Checklist
- Verify the issuer identity: the supplied filing is for Selecta Biosciences, Inc., while the request identifies Cartesian Therapeutics, Inc.
- Confirm the company’s post-quarter financing activity and whether additional capital was raised before the expected mid-2018 cash runway.
- Review subsequent clinical results, enrollment, safety events and regulatory developments for SEL-212.
- Assess the financial impact of Sanofi’s termination and the company’s ability to replace lost collaboration funding.
- Reconcile cash, short-term investments, debt maturities and lender covenant requirements.
- Evaluate deferred revenue recognition and the remaining obligations under the Spark agreement.
- Review third-party manufacturing and supply risks, particularly dependence on 3SBio for pegsiticase.